Sarcomes J1S-MC-JV01 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Paris SOPHIE PIPERNO-NEUMANN
Sarcomes J1S-MC-JV02 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Paris SOPHIE PIPERNO-NEUMANN
Sein métastatique RH+ PALATINE - UC-0140/1814 ADVANCED BREAST CANCER: THERAPY INTEGRATING LOCOREGIONAL TREATMENT IN DE NOVO,;TREATMENT NAIVE, STAGE IV ER+, HER2- BREAST CANCER PATIENTS RECEIVING LETROZOLE AND;PALBOCICLIB Paris, Saint-Cloud
Appareil Digestif REGIRI (PRODIGE 58) A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas Paris, Saint-Cloud
Appareil Digestif SAMCO (FFCD1603-PRODIGE 54) Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI). Paris BRUNO BUECHER
Gynécologie - Ovaires TG4050.01 A phase I trial evaluating a mutanome-directed immunotherapy in patients with high grade serous carcinoma (HGSC) of the ovary, fallopian tube or peritoneum who experience an asymptomatic relapse Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
Sein métastatique RH+ SERENA-2 (D8530C00002) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase;2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus;Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast;Cancer Paris FRANCOIS-CLEMENT BIDARD
Gynécologie - Ovaires AGO-OVAR 2.29 Atezolizumab in combination with Bevacizumab and Chemotherapy;versus Bevacizumab and Chemotherapy;in recurrent ovarian cancer À a randomized Phase III trial;An ENGOT Trial Paris MANUEL RODRIGUES
Gynécologie - Ovaires RAMP-201 (VS-6766-201 / ENGOT-ov60) A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Paris MANUEL RODRIGUES